Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, sold 9,514 shares on Jan. 20, 2026, totaling $784,700 at $82.48 per share. This sale reduced his direct holdings by 8.91%, from 106,780 to 97,266 shares. The transaction was for tax purposes only and should not impact investing decisions. Protagonist Therapeutics has a market cap of $5.11 billion and a high P/E ratio of 113.68, indicating growth potential. The company highlighted significant projected growth at the J.P. Morgan Healthcare Conference, with its stock soaring 123% in 2025. Wall Street analysts rate it a “strong buy.”

Read more at Nasdaq: Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes